Analyze Diet
Journal of labelled compounds & radiopharmaceuticals2026; 69(10-11); e70036; doi: 10.1002/jlcr.70036

Synthesis and Characterization of 2-(1-Hydroxyethyl)Promazine Sulfoxide-d4 HCl as an Internal Standard for the Accurate Quantitation of 2-(1-Hydroxyethyl)Promazine Sulfoxide in Equine Urine.

Abstract: Acetylpromazine, 1-{10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethenone, CHNOS, 326.46 g·mol is a phenothiazine derivative at one time used in human medicine as an antipsychotic medication but now predominantly used in veterinary medicine as a sedative/tranquilizer and referred to as acepromazine. In performance horses its use is regulated by using a 10 ng/mL threshold for the major urinary metabolite 2-(1-hydroxyethyl) promazine-sulfoxide (HEPS) in equine urine. To enable accurate quantitation of HEPS in equine urine we have synthesized and purified hydroxyethylpromazine sulfoxide-d (HEPS-d) to be used as a stable isotopically labeled internal standard. Although labeled HEPS is commercially available (CAS 1346605-30-8), to the best of our knowledge there is no published synthetic procedure in the scientific literature. Here we demonstrate a viable synthetic procedure consisting of four major steps: (i) freebasing the Acepromazine maleate salt, (ii) H-D exchange of Acepromazine at room temperature, (iii) reduction of the ketone with NaBD, and (iv) oxidation of the thioether via hydrogen peroxide and acetic acid. This deuterated internal standard will allow for precise LC/MS quantitation of HEPS at regulatory threshold concentrations, enabling accurate detection and quantitation of picogram/mL concentrations in equine urine samples, thereby supporting regulatory compliance for equine medication control programs.
Publication Date: 2026-09-01 PubMed ID: 42676282PubMed Central: PMC13531255DOI: 10.1002/jlcr.70036Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This study presents the synthesis and purification of a deuterated internal standard, 2-(1-hydroxyethyl)promazine sulfoxide-d4 hydrochloride (HEPS-d4 HCl), for accurately measuring the concentration of 2-(1-hydroxyethyl)promazine sulfoxide (HEPS) in horse urine.
  • This development supports the precise quantitation of HEPS to monitor and regulate the use of acepromazine in performance horses.

Background

  • Acepromazine: A phenothiazine derivative previously used as an antipsychotic in humans, now primarily used in veterinary medicine as a sedative/tranquilizer for animals, including horses.
  • Regulatory Importance: The use of acepromazine in performance horses is regulated with a threshold concentration of 10 ng/mL for its major urinary metabolite, HEPS, in equine urine, to ensure compliance and fair competition.
  • Analytical Challenge: Accurate quantitation of HEPS at very low concentrations (picograms per milliliter) requires a reliable internal standard that can correct for variability in detection methods.

Objective

  • To synthesize and purify a stable isotopically labeled internal standard (HEPS-d4) to enable precise and accurate measurement of HEPS levels in equine urine using liquid chromatography-mass spectrometry (LC/MS).
  • Address the lack of published synthetic procedures despite the commercial availability of labeled HEPS compounds.

Synthetic Procedure

  • The synthesis involves four major steps:
    • (i) Freebasing Acepromazine Maleate Salt: Transforming the salt form of acepromazine into its freebase form to prepare it for further chemical modification.
    • (ii) H-D Exchange at Room Temperature: Introducing deuterium atoms by replacing hydrogen on Acepromazine, enhancing isotopic labeling for use as an internal standard.
    • (iii) Reduction of the Ketone with Sodium Borodeuteride (NaBD4): Converting the ketone group into its corresponding alcohol while incorporating deuterium atoms, critical for creating the labeled hydroxyethyl side chain.
    • (iv) Oxidation of the Thioether: Using hydrogen peroxide and acetic acid to oxidize the sulfur atom in the molecule to a sulfoxide, completing the formation of the labeled 2-(1-hydroxyethyl)promazine sulfoxide-d4.
  • This multi-step synthetic pathway ensures incorporation of four deuterium atoms, providing a distinguishable mass signature for LC/MS analysis.

Analytical and Practical Significance

  • Internal Standard Role: The deuterated HEPS serves as a precise internal standard in LC/MS, compensating for sample preparation variability, matrix effects, and instrumental fluctuations.
  • Regulatory Compliance: Enables accurate quantitation of HEPS at threshold levels relevant for equine medication monitoring programs, facilitating enforcement of drug use regulations in performance horses.
  • Detection Sensitivity: Allows detection of minute concentrations (picogram/mL range) of HEPS in urine, essential for sensitive doping control.
  • Scientific Contribution: Provides the first documented synthetic route for HEPS-d4, filling a gap in published methodology and supporting future research and regulatory analysis.

Summary

  • This study successfully synthesizes a stable isotopically labeled internal standard for HEPS using a four-step chemical procedure.
  • The internal standard improves the reliability of LC/MS quantification at low concentration levels critical for monitoring acepromazine use in horses.
  • The work supports regulatory frameworks by enabling precise detection and adherence to medication thresholds, promoting fair competition in equestrian sports.

Cite This Article

APA
Holmes JC, Smith BC, Awuah SG, Eisenberg R, Lehner AF, Fenger CK, Maylin GA, Brewer K, Tobin T. (2026). Synthesis and Characterization of 2-(1-Hydroxyethyl)Promazine Sulfoxide-d4 HCl as an Internal Standard for the Accurate Quantitation of 2-(1-Hydroxyethyl)Promazine Sulfoxide in Equine Urine. J Labelled Comp Radiopharm, 69(10-11), e70036. https://doi.org/10.1002/jlcr.70036

Publication

ISSN: 1099-1344
NlmUniqueID: 7610510
Country: England
Language: English
Volume: 69
Issue: 10-11
Pages: e70036
PII: e70036

Researcher Affiliations

Holmes, Justin C
  • Department of Chemistry, University of Kentucky, Lexington, Kentucky, USA.
Smith, Ballard C
  • Department of Chemistry, University of Kentucky, Lexington, Kentucky, USA.
Awuah, Samuel G
  • Department of Chemistry, University of Kentucky, Lexington, Kentucky, USA.
  • Center for Pharmaceutical Research and Innovation, College of Pharmacy and Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.
Eisenberg, Rodney
  • Frontier BioPharm, LLC, Richmond, Kentucky, USA.
Lehner, Andreas F
  • MSU Veterinary Diagnostic Laboratory, Section of Toxicology, Michigan State University, Lansing, Michigan, USA.
Fenger, Clara K
  • Equine Integrated Medicine, Georgetown, Kentucky, USA.
Maylin, George A
  • New York Drug Testing and Research Program, Ithaca, New York, USA.
Brewer, Kimberly
  • Wellington, Florida, USA.
Tobin, Thomas
  • The Department of Veterinary Science and the Maxwell H. Gluck Equine Research Center, Martin-Gatton College of Agriculture, Food and Environment and the Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, USA.

MeSH Terms

  • Animals
  • Horses / urine
  • Acepromazine / urine
  • Acepromazine / chemical synthesis
  • Acepromazine / chemistry
  • Acepromazine / analogs & derivatives
  • Reference Standards
  • Chemistry Techniques, Synthetic
  • Sulfoxides / urine
  • Sulfoxides / chemical synthesis
  • Sulfoxides / chemistry

Grant Funding

  • KY014066 / National Institute of Food and Agriculture, U.S. Department of Agriculture

Conflict of Interest Statement

The authors declare no conflicts of interest.

References

This article includes 14 references
  1. Algren DA, Ashworth A. Acute Acepromazine Overdose: Clinical Effects and Toxicokinetic Evaluation. Journal of Medical Toxicology 11 (2015): 121–123.
    doi: 10.1007/s13181-014-0416-1pmc: PMC4371025pubmed: 25059809google scholar: lookup
  2. Tobin T., Drugs and the Performance Horse (Charles C Thomas, 1981).
  3. Ballard S, Shults T, Kownacki AA, Blake JW, Tobin T. The Pharmacokinetics, Pharmacological Responses and Behavioral Effects of Acepromazine in the Horse. Journal of Veterinary Pharmacology and Therapeutics 5 (1982): 21–31.
  4. Wood T, Stanley S, Woods WE, Henry P, Watt D, Tobin T. Evaluation of Threshold Doses of Drug Action in the Horse Using Hematocrit Values as an Indicator. Research Communications in Chemical Pathology and Pharmacology 75 (1992): 231–241.
    pubmed: 1570406
  5. Knych HK, Seminoff K, McKemie DS, Kass PH. Pharmacokinetics, Pharmacodynamics, and Metabolism of Acepromazine Following Intravenous, Oral, and Sublingual Administration to Exercised Thoroughbred Horses. Journal of Veterinary Pharmacology and Therapeutics 41 (2018): 522–535.
    doi: 10.1111/jvp.12494pubmed: 29457257google scholar: lookup
  6. Wieder M, Gray B, Hincks P. Identification of Acepromazine and Its Metabolites in Horse Plasma and Urine by LC–MS/MS and Accurate Mass Measurement. Chromatographia 75 (2012): 365.
    doi: 10.1007/s10337-012-2234-4google scholar: lookup
  7. Schneiders FI, Noble GK, Boston RC, Dunstan AJ, Sillence MN, McKinney AR. Acepromazine Pharmacokinetics: A Forensic Perspective. Veterinary Journal 194 (2012): 48–54.
    doi: 10.1016/j.tvjl.2012.03.017pubmed: 22534188google scholar: lookup
  8. RMTC CTS. Monograph Series: Acepromazine. 2020.
  9. Federal Trade Commission. HISA Anti‐Doping and Medication Control Rule. 2023.
  10. RMTC. Withdrawal Guidance Advisory. 2023.
  11. Holloway K. Personal Communication to T Tobin (Racing Commissioners International, 2026). .
  12. Moss MS, Clarke EG. A Review of Drug “Clearance Times” in Racehorses. Equine Veterinary Journal 9 (1977): 53–56.
  13. Tobin T, Stirling KH, Brewer K. World Rules for Equine Drug Testing and Therapeutic Medication Regulation: 2012 Policy of the National Horsemen's Benevolent and Protective Association, Inc. 2012.
  14. . Frontier BioPharm. .

Citations

This article has been cited 0 times.